The Vytorin controversy exposes shortcomings of surrogate endpoints

May 2008

The Vytorin controversy exposes shortcomings of surrogate endpoints.

Drugs are all too often approved and used due to their ability to change surrogate endpoints...blood pressure, lipids, serum glucose, etc.

The "ENHANCE" trial is a good reminder that these endpoints are not always accurate indicators of overall outcomes.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

The Vytorin controversy exposes shortcomings of surrogate endpoints
Generics generics of Toprol-XL, Wellbutrin XL, and other long-acting products don't work as well as the brands
Generics A new Auralgan is replacing the older Auralgan
Pediatrics treating GERD in children
Gastroenterology new concerns about the safety of sodium phosphate bowel preps
Diabetes You'll hear that pioglitazone (Actos) slows atherosclerosis
Respiratory & Allergy People are hearing that Singulair might increase suicide risk
Women's Health Women often ask whether hormonal contraceptives are safe after age 35
Psychiatry promoting a new antidepressant called Pristiq
Psychiatry whether dementia drugs are worth using
Dermatology topical treatments for chronic wound debridement
Anticoagulants heparin recall rekindles concern over the safety of drugs and products made overseas